We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Expression, Microbiome Features Provide Pre-Treatment Lung Function Clues for Pediatric Patients

By LabMedica International staff writers
Posted on 15 Mar 2022
Print article
Image: NovaSeq 6000 offers deeper and broader coverage through advanced applications for a comprehensive view of the genome (Photo courtesy of Illumina)
Image: NovaSeq 6000 offers deeper and broader coverage through advanced applications for a comprehensive view of the genome (Photo courtesy of Illumina)

Microbial community and host gene expression features in lung samples may provide pre-treatment clues to risky lung function features in children receiving bone marrow transplants from healthy donor individuals.

Impaired baseline lung function is associated with mortality after pediatric allogeneic hematopoietic cell transplantation (HCT), yet limited knowledge of the molecular pathways that characterize pre-transplant lung function has hindered the development of lung-targeted interventions.

Clinical Scientists at the University of California at San Francisco (San Francisco, CA, USA) and their colleagues used metatranscriptomic RNA sequencing to profile microbiome and host gene expression features in bronchoalveolar lavage samples collected from 104 children in the Netherlands in roughly the week or two leading up to their allogeneic HCT treatments, comparing those patterns with results from matched pulmonary function tests. Sample RNA was combined with control spike-in RNA and underwent reverse transcription, library preparation, and 125-nucleotide paired-end sequencing on a NovaSeq 6000 instrument (Illumina, San Diego, CA, USA) to a target depth of 40 million read pairs per sample.

Among the 54 children showing signs of pulmonary restriction, impaired oxygen diffusion, lung capacity, or other altered pulmonary functions based on Global Lung Index cutoff scores, the team saw an overrepresentation of Staphylococcus and other skin or nasal passage-related microbes, but lower-than-usual levels of commensal microbes that are typically detected in the supraglottic region of the throat.

Depletion of commensal supraglottic taxa, such as Haemophilus, and enrichment of nasal and skin taxa, such as Staphylococcus, in the bronchoalveolar lavage (BAL) microbiome were associated with worse measures of lung capacity and gas diffusion. In addition, BAL gene expression signatures of alveolar epithelial activation, epithelial-mesenchymal transition, and down-regulated immunity were associated with impaired lung capacity and diffusion, suggesting a post-injury profibrotic response. Detection of microbial depletion and abnormal epithelial gene expression in BAL enhanced the prognostic utility of pre-HCT pulmonary function tests for the outcome of post-HCT mortality.

Joseph DeRisi, PhD, a Molecular Biologist and a senior co-author of the study, said, “Impaired baseline lung function is associated with mortality after pediatric allogeneic hematopoietic cell transplantation (HCT), yet limited knowledge of the molecular pathways that characterize pre-transplant lung function has hindered the development of lung-targeted interventions.”

The authors concluded that among children preparing to undergo allogeneic HCT, pulmonary function testing abnormalities were common and consisted mostly of restriction and impaired diffusion. Abnormalities were associated with pulmonary microbiome depletion, profibrotic signaling, and post-HCT mortality. The study was published on March 9, 2022 in the journal Science Translational Medicine.

Related Links:
University of California at San Francisco 
Illumina 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fixed Speed Tube Rocker
GTR-FS
New
TRAb Immunoassay
Chorus TRAb

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.